FDA has granted Descartes-08, an mRNA chimeric antigen receptor T cell therapy, a rare pediatric disease designation for the treatment of juvenile dermatomyositis.
Search results for: pain
Reproductive Health, Biosimilars & More in Focus at SOTA 2025
Reproductive health, biosimilars, IgG4-related disease and much more—five speakers give us a sneak peek into important topics being addressed at the ACR’s 2025 State-of-the-Art Clinical Symposium, April 4–6.
Precision Medicine on a Population Level: Can Digital Health Technology Improve Access to Rheumatologic Care?
Over our 25 years as rheumatologists, care has advanced greatly. We each completed our rheumatology training in the late 1990s when both infliximab and etanercept first arrived on the U.S. market, ushering in the era of biologics in rheumatology. Since this time, our greater understanding of the immunologic basis of many rheumatic diseases has translated…
RA: How High Is the Toll?
Patients with RA not only suffer from functional limitations, but also face increased healthcare costs, primarily due to prescription drug use, says Dr. Yinan Huang.
Rheuminations: Imagine a Better World for Clinicians & Our Patients
The world didn’t end on Jan. 1, 2000. The Y2K bug didn’t crash airplanes and liquidate bank assets. We were, overall, hopeful for the future—a new millennium full of futuristic visions of a techno-utopia. Fast forward a quarter of a century and we now live in that technologically advanced age that once seemed so far…
Sleep Disorders & Rheumatic Disease
ACR Convergence 2024—With poor sleep a major complaint among patients with rheumatologic diseases, physicians should hone their understanding of how the body regulates sleep and how this system can be disrupted, and tailor their management plans to help patients with these issues, panelists said in a session at ACR Convergence. For some patients, their struggles…
Under Pressure: Understanding Dysautonomia & POTS
Brit Adler, MD, provided a detailed analysis into the symptoms and management of patients with postural orthostatic tachycardia syndrome.
FDA Approves Bimekizumab-bkzx (Bimzelx) for 3 New Rheumatic Indications
The FDA has approved bimekizumab-bkzx for the treatment of adults with psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis.
ARP Celebrates 58 Years of Achievements & Transformations, Identifies Challenges
ACR Convergence 2024—In a wide-ranging and engaging discussion, members of the Association of Rheumatology Professionals (ARP) tracked their progress over the years across clinical practice, research production and representation in the field, while outlining challenges and opportunities to come. The session at ACR Convergence included a panel and an audience full of past presidents of…
The Identification & Management of Hypophosphatasia
With the U.S. Food & Drug Administration’s approval in 2014 of asfotase alfa for replacement of tissue-non-specific alkaline phosphatase (TNSALP or TNAP) in juvenile-onset hypophosphatasia (HPP), rheumatologists have a responsibility to recognize the more subtle manifestations of this condition in adults to avoid missed treatment opportunities for fractures, dental loss and musculoskeletal pain. Hypophosphatasia is…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 243
- Next Page »